1. Giannini E, Fasoli A, Botta F, Testa R. Wilson’s Disease with concomitant Thalassemia and Factor V Deficiency. Ital J Gastroenterol Hepatol 1998; 30: 633-635.
2. Marenco S, Giannini EG, Savarino V. Patent paraumbilical vein-induced hepatic encephalopathy. Clin Gastroenterol Hepatol 2010; 10: A28.
3. Del Nero L, Mazza F, Cittadini G, Savarino V, Giannini EG. “Starry liver”: an unexpected diagnosis. ACG Case Rep J 2015; 2: 77-78.
4. Plaz Torres MC, Romana C, Coppo C, Zentilin P, Grillo F, Savarino V, Giannini EG. Hepatobiliary and pancreatic: A rare cause of portal hypertension. J Gastroenterol Hepatol 2016; 31: 11.
5. Del Nero L, Moscatelli A, Fazio V, Pellegatta G, Bongioanni F, Sambuceti G, Savarino V, Giannini EG. Positive positron emission tomography in a patient with esophageal leiomyoma. Am J Gastroenterol 2016; 111: 767.
6. Lo Pumo S, Cacciato V, De Maria C, Giannini EG. The hepatologist in the haematologist field: a rare cause of non-cirrhotic portal hypertension. Ann Hematol Oncol 2018; 51: 1190.
7. Crespi M, Demarzo MG, Brunacci M, Pellegatta G, Ferrando F, Ballestrero A, Grillo F, Savarino V, Giannini EG. Improvement in Waldenstrom’s macroglobulinemia after succesful treatment of HCV with direct-acting antivirals. Ann Hepatol 2018; 17: 1072-1077.
8. Caranci G, Cordano C, Giannini E, Bandini F. Acquired hepatocerebral degeneration in the absence of portosystemic shunting. J Clin Neurol 2019; 15:128-129.
9. De Maria C, Ghidotti I, Grillo F, Giannini EG. Successful DAAs treatment and global improvement in a cirrhotic patient with concomitant HCV infection and autoimmune hepatitis.
Dig Dis Sci 2019: 64: 591-593.
10. Cacciato V, Casagrande E, Bodini G, Furnari M, Marabotto E, Grillo F, Giannini EG.
Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV. Ann Hepatol 2020; 19: 222-225.
41
Lettere
1. Giannini E, Botta F, Romagnoli P, Testa R. Oral or intravenous lidocaine administration to perform MEGX test. Dig Dis Sci 2000; 45: 1011-1012.
2. Giannini E, Fasoli A, Botta F, Romagnoli P, Malfatti F, Chiarbonello B, Testa R. Is there a role for multiple quantitative liver function tests? Dig Liver Dis 2000; 32: 644.
3. Giannini E, Testa R. Is aspartate aminotransferase enough? Am J Gastroenterol 2000; 95: 3687-3688.
4. Giannini E, Testa R. Chronic hepatitis C in different populations: similar patterns of ALT alteration characterize similar clinical subgroups. Hepatology 2001; 33: 313.
5. Giannini E, Risso D, Testa R. Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. Am J Gastroenterol 2001; 96: 918-919.
6. Giannini E, Testa R. Persistently normal aminotransferase in chronic HCV infection: is it time to redefine parameters of “normality”? Dig Liver Dis 2001; 33: 202-203.
7. Giannini E, Barreca T, Testa R. Leptin in nonalcoholic steatohepatitis: is it one of the “hits”? Am J Gastroenterol 2001; 96: 2519-2520.
8. Giannini E, Ceppa P, Testa R. Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy? J Hepatol 2001; 35: 432-433.
9. Giannini E, Testa R. Surveillance for hepatocellular carcinoma in liver cirrhosis: have programmes improved because patients have? Gut 2002; 51: 456-457.
10. Giannini E, Testa R. Can changing counseling strategy change the picture of the chronic hepatitis C patient population? Arch Intern Med 2002; 162: 2497.
11. Giannini E, Botta F, Testa R. Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. Gastroenterology 2003; 125: 993-994.
12. Giannini E, Testa R. Noninvasive diagnosis of fibrosis: The truth is rarely pure and never simple.
Hepatology 2003; 35: 1312-1313.
13. Giannini E, Testa R. The metabolic syndrome: all criteria are equal, but some criteria are more equal than others. Arch Intern Med 2003; 163: 2787-2788.
14. Giannini E, Testa R. Non-invasive assessment of liver function: trying not to miss an opportunity. Aliment Pharmacol Ther 2004; 19: 827-828.
15. Giannini EG, Botta F, Testa R.Prediction of oesophageal varices with platelet count/spleen diameter ratio or platelets alone. Gut 2004; 53: 914-915.
16. Giannini EG, Testa R. Reply to Farinati et al.: classification of 'intermediate stage', untreated hepatocellular carcinoma patients: the neighbour's grass is not so green. J Intern Med 2004;
256: 531.
17. Giannini EG, Romagnoli P, Testa R. Eligibility criteria for antiviral therapy in HCV-positive patients: similar things to (almost) similar people. Am J Gastroenterol 2006; 101: 406-407.
18. Giannini EG, Savarino V. HCV and fat: something is missing. J Hepatol 2009; 50: 421-422.
19. Giannini EG, Savarino V. Blessed are those who have not seen and yet have believed. Am J Gastroenterol 2010; 105: 227-228.
42 20. Giannini EG, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F for the Italian Liver Cancer (ITA.LI.CA.) group.
TACE in Child-Pugh class B patients with HCC: between the devil and the deep blue sea. Liver Int 2010; 30: 923-924.
21. Giannini EG, Farinati F, Trevisani F. Alpha-fetoprotein in hepatocellular carcinoma surveillance:
wake not the dead. Hepatology 2011; 54: 376-377.
22. Savarino E, Assandri L, Giannini EG, Savarino V. Small intestinal bacterial overgrowth and Helicobacter pylori – Can they be cause of thrombocytopenia in patients with chronic liver disease ? Am J Gastroenterol 2011; 106: 1171-1172.
23. Giannini EG, Marenco S, Baldissarro E, Fazio V. Letter to the Editors: IL28B rs 12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin. Aliment Pharmacol Ther 2011; 34: 398-400.
24. Abdulhadi–Ali MM, Alsaudi D, Agha A, Ibraheem–Alqahtani N, Furnari M, Savarino V, Giannini EG. Full-dose peginterferon alfa-2a and low-dose ribavirin treatment of genotypes 1 and 4 chronic hepatitis C patients with end-stage renal disease. Clin Gastroenterol Hepatol 2011; 9:
1004.
25. Farinati F, Giannini E, Trevisani F. TACE treatment in hepatocellular carcinoma: what should we do now? J Hepatol 2012; 57: 221-222.
26. Giannini EG, Savarino V. Comment to: Platelet count/spleen diameter ratio for non-invasive diagnosis of oesophageal varices: Is it useful in compensated cirrhosis? Dig Liver Dis 2012; 44:
965.
27. Giannini EG, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F, for the Italian Liver Cancer (ITA.LI.CA) group. Ten-year outcome of radiofrequency thermal ablation for hepatocellular carcinoma: an Italian experience. Am J Gastroenterol 2012; 107: 1588-1589.
28. Giannini EG, Savarino V. Which anticoagulant drug should be used treat portal vein thrombosis in patients with chronic liver disease? Clin Gastroenterol Hepatol 2013; 11: 103.
29. Giannini EG, Trevisani F. Surveillance for hepatocellular carcinoma: Just do it! Am J Gastroenterol 2013; 108: 1013-1014.
30. Giannini EG, Farinati F, Trevisani F. Adequate interval for hepatocellular carcinoma surveillance. Am J Gastroenterol 2013; 108: 1174.
31. Giannini EG, Savarino V. Predicting post-transplant prognosis of patients with hepatocellular carcinoma: what lies beneath alpha-fetoprotein? Liver Transpl 2013; 19: 1166-1167.
32. Giannini EG, Savarino V. Platelet count and survival of compensated cirrhotic patients with small HCC treated with surgery. Hepatology 2014; 59: 1649.
33. Giannini EG, Cucchetti A, Vitale A. Prognostic prediction and identification of candidates to salvage liver transplantation in patients with early hepatocellular carcinoma. Liver Transpl 2014; 20: 1150-1151.
34. Giannini EG, Stravitz RT, Caldwell SH. Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis. Hepatology 2014; 60: 1442.
35. Giannini EG, Trevisani F. Improving survival of cirrhotic patients with hepatocellular carcinoma through application of standard of care. Hepatology 2014; 60: 1446-1447.
43 36. Giannini EG, Trevisani F. Accuracy of alpha-fetoprotein for the detection of hepatocellular
carcinoma: one more nail in the coffin. Clin Gastroenterol Hepatol 2014; 12: 2138-2139.
37. Giannini EG, Trevisani F. Screening for hepatocellular carcinoma in chronic liver disease. Ann Intern Med 2015; 162: 239-240.
38. Bodini G, Giannini EG, Savarino E, Savarino V. Adalimumab trough levels and response to biological treatment in patients with Inflammatory Bowel Disease: a useful cut-off in clinical practice. Am J Gastroenterol 2015; 110: 472-473.
39. Giannini EG, Stravitz RT, Caldwell SH. Portal vein thrombosis and chronic liver disease progression: the closer you look the more you see. Hepatology 2016; 63: 342-343.
40. Giannini EG, Savarino V. An independent validation of the mortality score for the short-term prognostic prediction in patients with chronic hepatitis C virus infection and advanced liver disease. Gut 2016; 65: 183-184.
41. Furnari M, Bodini G, Giannini EG, Savarino V. Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease. Aliment Pharmacol Ther 2016; 43:
1240-1241.
42. Giannini EG, Savarino V. Non-invasive assessment of varices needing treatment in patients with cirrhosis: no one should be left behind. Hepatology 2017; 65: 2131.
43. Giannini EG, Bodini G, Savarino V. A nodule, is a nodule, is a nodule: may alpha-fetoprotein make the difference? Am J Gastroenterol 2017; 112: 1340.
44. Marabotto E, Furnari M, Savarino V, Giannini EG, Savarino E. Letter: It is time to adopt new objective parameters to accurately identify patients with functional heartburn. Aliment Pharmacol Ther 2018; 48: 107-108.
45. Giannini EG, Bodini G, Furnari M, Marabotto E. NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis. J Hepatol 2018; 69: 972-973.
46. Giannini EG, Bodini G, Furnari M, Marabotto E. Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm. Liver Int 2018; 38: 2101.
47. Crespi M, Ghidotti I, Bodini G, Furnari M, Marabotto E, Giannini EG. Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations. Dig Liver Dis 2019; 51: 173-174.
48. Giannini EG, Bodini G, Furnari M, Marabotto E. A closer look at factors associated with bleeding in cirrhotic patients. Am J Gastroenterol 2019; 114: 364-365.
49. Giannini EG, Demarzo M, Bodini G. Reproducibility and transportability of the absence of incremental infectious adverse events in patients with higher anti-TNF drug levels. Inflamm Bowel Dis 2019; 25: e73.
50. Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, Torre F. Regression of fibrosis after DAAs treatment of patients with HCV cirrhosis: transposability to non-decompensated patients. J Exp Clin Hepatol 2019; 9: 546.
51. Giannini EG, Bodini G, Furnari M, Marabotto E. Hepatocellular carcinoma intermediate stage sub-classification systems: one, none, and one hundred thousand. Liver Cancer 2019; 8: 524-526.
44 52. Giannini EG, Bodini G, Marabotto E, Plaz Torres MC, Zentilin P, Furnari M. Risk factors for bleeding following oesophageal band ligation: providing further evidence to ameliorate clinical practice. Dig Liver Dis 2020; 52: 792-793.
53. Marabotto E, Ziola S, Djahandideh Sheijani A, Giannini EG. COVID-19 and liver disease: not all evil comes to harm. Liver Int 2021; 41: 237-238.
54. Giannini EG, Bodini G, Furnari M, Marabotto E. Proactive measures aimed at improving appropriateness of use of proton pump inhibitors in clinical practice. Clin Gastroenterol Hepatol 2021; 19: 410.
55. Giannini EG, Plaz Torres MC, Vitale A, Farinati F, Trevisani F; ITA.LI.CA group. Liver resection for patients with intermediate stage hepatocellular carcinoma: beyond rigid staging systems towards a more personalized therapeutic approach. J Gastrointest Surg 2021; 25: 1078-1079.
56. Demarzo MG, Bodini G, Vanello M, Martini M, Giannini EG. Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Aliment Pharmacol Ther 2021;53: 1044-1045.
57. Papadia FS, Marabotto E, Mascherini M, Rubartelli A, Camerini G, Giannini EG. Sleeve gastrectomy may double the risk of esophageal adenocarcinoma in morbidly obese patients.
Surg Obes Relat Dis 2021; 17: 1029-1030.
58. Giannini EG, Bodini G, Marabotto E, Furnari M. Applicability of parameters for the non-invasive diagnosis of esophageal varices needing treatment to cured HCV patients. Clin Infect Dis 2021;
72: 1862-1863.
59. Marabotto E, Savarino E, De Bortoli N, Giannini EG. Refractoriness to treatment suggests that clinical evaluation should go beyond the diagnosis of reflux disease. Clin Gastroenterol Hepatol 2021; 19: 1077-1078.
60. Giannini EG, Marenco S. High acceptance rate of COVID-19 vaccination in liver transplant recipients. J Hepatol 2021May 27:S0168-8278(21)00344-5. doi: 10.1016/j.jhep.2021.05.009 61. Giannini EG, Demarzo M, Bodini G. Elevated adherence to vaccination against SARS-CoV-2
among patients with Inflammatory Bowel Disease. J Crohns Colitis. 2021 Jun 15:jjab104. doi:
10.1093/ecco-jcc/jjab104
62. Demarzo M, Bodini G, Giuliana E, Zentilin P, Giannini EG. Letter: predictive factors of discontinuation treatment in inflammatory bowel disease - anti-TNF trough levels and antibodies. Aliment Pharamcol Ther 2021
45